PPCB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Propanc Biopharma Inc (PPCB) is not a good buy for a beginner, long-term investor at this time. The stock shows no strong trading signals, lacks positive catalysts, and its financial performance is weak. Additionally, technical indicators suggest a bearish trend, and there is no significant news or trading activity to support a bullish outlook.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 34.717, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is near its key support level at 0.1, but overall, the trend is bearish.
NULL identified. No recent news or significant trading activity from hedge funds, insiders, or influential figures.
and a significant net income loss (-$4,023,640). No recent news or events to drive positive sentiment.
In Q2 2026, revenue remained at $0 with no growth. Net income loss increased by 835.33% YoY to -$4,023,640. EPS dropped significantly by -99.07% YoY to -0.3, indicating worsening profitability.
No analyst ratings or price target changes available for PPCB.
